Figure 2.

Associations between MSI screening status, beta-catenin overexpression and survival in all patients and in subgroups according to disease stage. Kaplan-Meier analysis of colorectal cancer specific survival according to: (A) MSI screening status in the full cohort (logrank p = 0.008**), (B) Beta-catenin score in the full cohort (logrank p = 0.116), (C) MSI screening status in stage I-II disease (logrank p =0.985), (D) Beta-catenin score in stage I-II disease (logrank p =0.725), (E) MSI screening status in stage III-IV disease (logrank p =0.032*) and (F) Beta-catenin score in stage III-IV disease (logrank p =0.034*).